Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

[Efficacy of rituximab combined with cyclophosphamide in a patient with systemic lupus erythematosus and peritoneal vasculitis refractory to conventional inmunosupressive therapy].

Garrido Rasco R, García Hernández FJ, González León R, Castillo Palma MJ, Ocaña Medina C, Sánchez Román J.

Reumatol Clin. 2009 Feb;5(1):28-30. doi: 10.1016/S1699-258X(09)70201-3. Epub 2009 Feb 28. Spanish.

2.

Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.

Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.

Lupus. 2010 Feb;19(2):213-9. doi: 10.1177/0961203309351541. Epub 2009 Dec 4.

PMID:
19965944
3.

[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.

Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Serbian.

PMID:
12583309
4.

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.

Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.

Nephrol Dial Transplant. 2011 Dec;26(12):3987-92. doi: 10.1093/ndt/gfr109. Epub 2011 Mar 8.

5.

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT.

Arthritis Rheum. 2002 Apr;46(4):995-1002.

PMID:
11953977
6.

[Experience with rituximab in the treatment of systemic erythematosus lupus].

García-Hernández FJ, Díaz-Cobos C, Callejas-Rubio JL, Ocaña-Medina C, Ortego-Centeno N, Sánchez-Román J, de Ramón-Garrido E, Camps-García MT.

Reumatol Clin. 2006 Jan;2(1):23-30. doi: 10.1016/S1699-258X(06)73016-9. Epub 2008 Dec 30. Spanish.

7.

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation.

Arthritis Rheum. 2010 Aug;62(8):2458-66. doi: 10.1002/art.27541.

8.
9.

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

Sfikakis PP, Boletis JN, Tsokos GC.

Curr Opin Rheumatol. 2005 Sep;17(5):550-7. Review.

PMID:
16093832
10.

[Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide. Value and limitations].

De Bandt M, Goycochea MV, Meyer O, Delahousse M, Palazzo E, M'Bappé P, Kahn MF.

Ann Med Interne (Paris). 1994;145(2):75-87. French.

PMID:
8024184
11.

Posterior reversible encephalopathy syndrome--an underrecognized manifestation of systemic lupus erythematosus.

Kur JK, Esdaile JM.

J Rheumatol. 2006 Nov;33(11):2178-83. Epub 2006 Sep 1. Review.

PMID:
16960925
12.

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.

Petri M, Jones RJ, Brodsky RA.

Arthritis Rheum. 2003 Jan;48(1):166-73.

13.

Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.

Arthritis Rheum. 2007 Apr;56(4):1263-72.

14.

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER).

Merrill J, Buyon J, Furie R, Latinis K, Gordon C, Hsieh HJ, Brunetta P.

Lupus. 2011 Jun;20(7):709-16. doi: 10.1177/0961203310395802. Epub 2011 Apr 8.

PMID:
21478286
15.

Rituximab therapy for childhood-onset systemic lupus erythematosus.

Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group.

J Pediatr. 2006 May;148(5):623-627. Erratum in: J Pediatr. 2006 Oct;149(4):586.

PMID:
16737873
16.

Rituximab in the treatment of refractory lupus nephritis with vasculitis.

Kadikoy H, Haque W, Ahmed S, Abdellatif A.

Saudi J Kidney Dis Transpl. 2012 Mar;23(2):334-7.

17.

Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.

Pinto LF, Velásquez CJ, Prieto C, Mestra L, Forero E, Márquez JD.

Lupus. 2011 Oct;20(11):1219-26. doi: 10.1177/0961203311409273. Epub 2011 Jul 22.

PMID:
21784778
18.

Rituximab monotherapy for remission induction of proliferative lupus nephritis flares: description of 3 cases.

Moroni G, Gallelli B, Banfi G, Leoni A, Messa P.

J Nephrol. 2010 May-Jun;23(3):357-61.

PMID:
20383866
19.

Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus.

Raptopoulou A, Linardakis C, Sidiropoulos P, Kritikos HD, Boumpas DT.

Lupus. 2010 May;19(6):744-7. doi: 10.1177/0961203309358601. Epub 2010 Feb 23.

PMID:
20179172
20.

[Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus].

Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P.

Ann Dermatol Venereol. 2006 Jan;133(1):53-5. French.

PMID:
16495854

Supplemental Content

Support Center